Результати пошуку - Ulrich Lücking

  • Показ 1 - 4 результатів із 4
Уточнити результати
  1. 1
    BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

    BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application за авторством Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau, Wolfram Steinke, Christoph A. Schatz, Dominik Mumberg, Karl Ziegelbauer

    Опубліковано 2012
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  2. 2
    Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9

    Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9 за авторством Pelin Ayaz, Dorothee Andres, Dennis Kwiatkowski, Carl‐Christian Kolbe, Philip Lienau, Gerhard Siemeister, Ulrich Lücking, Christian M. Stegmann

    Опубліковано 2016
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  3. 3
    The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models

    The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models за авторством Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking, Julien Lefranc, Lars Wortmann, Philip Lienau, Benjamin Bader, Ulf Bömer, Dieter Moosmayer, Uwe Eberspächer, Sven Golfier, Christoph A. Schatz, Simon J. Baumgart, Bernard Haendler, Pascale Lejeune, Andreas Schlicker, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, Dominik Mumberg

    Опубліковано 2019
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  4. 4
    Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

    Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer за авторством Ulrich Lücking, Arne Scholz, Philip Lienau, Gerhard Siemeister, Dirk Kosemund, Rolf Bohlmann, Hans Briem, Ildiko Terebesi, Kirstin Meyer, Katja Prelle, Karsten Denner, Ulf Bömer, Martina Schäfer, Knut Eis, Ray Valencia, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Karl Ziegelbauer, Bert Klebl, Axel Choidas, Peter Nußbaumer, Matthias Baumann, Carsten Schultz‐Fademrecht, Gerd Rühter, Jan Eickhoff, Michael Brands

    Опубліковано 2017
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: